For the Detection of Influenza A, Influenza B, and SARS-CoV-2
The GRD FluV19 Multiplex RT-PCR Assay (RUO) detects the presence of SARS-CoV-2, Influenza A, and Influenza B RNA in specimens. Additionally, sample integrity is also assessed in each sample by detecting RNA of the human ribonuclease P (RNase P) transcript available on in viable human cells. The FluVI 9 multiplex assay has three key features that distinguish it from other combined Influenza/SARS CoV-2 assays: 1) detection of RNaseP as an endogenous extraction control, 2) use of a plasmid construct that without any manipulation, serves as a control for PCR efficiency and that can be stably stored at 4 °C, and 3) use of a passive reference dye for normalization of amplification background noise. Combined, these features, along with a robust and easy-to-use extraction reagents, confer improved design, improved sensitivity, and a simplified workflow for Influenza and SARS-CoV-2 detection.
The GRD FluV19 Multiplex RT-PCR assay offers unique advantages over other SARS-CoV-2 assays. Specifically, in addition to detection of SARS-CoV-2, the GRD FluV19 Multiplex RT-PCR assay also offers detection of lnfluenza A and Influenza B while simultaneously ensuring that integrity of human specimens is also maintained through detection of human ribonuclease P (RNase P) RNA which is only present within viable cells. Refer to the chart below for comparison between the ThermoFisher TaqPath COVID Multiplex Assay and the GRD FluV19 Multiplex Assay.
When the FluV19 multiplex RT-PCR assay was compared against the CDC FluSC2 and Thermo Fisher COVID19 FluA/B assays, all assays were equivalent in accuracy of detection of the Influenza B and SARS-CoV-2. However, analytical statics of the FluV19 Multiplex Assay for the detection of lnfluenza A in human specimens demonstrated increased performance in analytical sensitivity and accuracy relative to both the CDC FluSC2 and Thermo Fisher COVID19 FluA/B assays. (Tables in the Reference Guide located in the Additional Info tab).